CA3209426A1 - Camptothecin compound, preparation method therefor, and application thereof - Google Patents
Camptothecin compound, preparation method therefor, and application thereof Download PDFInfo
- Publication number
- CA3209426A1 CA3209426A1 CA3209426A CA3209426A CA3209426A1 CA 3209426 A1 CA3209426 A1 CA 3209426A1 CA 3209426 A CA3209426 A CA 3209426A CA 3209426 A CA3209426 A CA 3209426A CA 3209426 A1 CA3209426 A1 CA 3209426A1
- Authority
- CA
- Canada
- Prior art keywords
- group
- compound
- hydrogen
- formula
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110159956 | 2021-02-05 | ||
| CN202110159956.6 | 2021-02-05 | ||
| CN202110533304 | 2021-05-17 | ||
| CN202110533304.4 | 2021-05-17 | ||
| CN202110718245 | 2021-06-28 | ||
| CN202110718245.8 | 2021-06-28 | ||
| CN202110936768.X | 2021-08-16 | ||
| CN202110936768 | 2021-08-16 | ||
| CN202111355330 | 2021-11-16 | ||
| CN202111355330.9 | 2021-11-16 | ||
| PCT/CN2022/074328 WO2022166762A1 (zh) | 2021-02-05 | 2022-01-27 | 喜树碱类化合物及其制备方法和应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3209426A1 true CA3209426A1 (en) | 2022-08-11 |
Family
ID=82741966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3209426A Pending CA3209426A1 (en) | 2021-02-05 | 2022-01-27 | Camptothecin compound, preparation method therefor, and application thereof |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20240158410A1 (enExample) |
| EP (3) | EP4613335A3 (enExample) |
| JP (3) | JP7821188B2 (enExample) |
| KR (3) | KR20250119655A (enExample) |
| CN (3) | CN117567478B (enExample) |
| AU (1) | AU2022216696A1 (enExample) |
| CA (1) | CA3209426A1 (enExample) |
| MX (1) | MX2023008716A (enExample) |
| WO (1) | WO2022166762A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12539336B2 (en) | 2022-07-15 | 2026-02-03 | Genequantum Healthcare (Suzhou) Co., Ltd. | Antibody, linkers, payload, conjugates and applications thereof |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK4516357T3 (da) | 2020-09-30 | 2026-04-27 | Duality Biologics Suzhou Co Ltd | Antitumorforbindelse, fremgangsmåde til fremstilling deraf og anvendelse deraf |
| EP4227310A4 (en) * | 2020-10-12 | 2024-11-06 | Sichuan Baili Pharmaceutical Co. Ltd. | CAMPTOTHECIN DERIVATIVE AND LIGAND-DRUG CONJUGATE THEREOF |
| AU2022216696A1 (en) * | 2021-02-05 | 2023-08-17 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Camptothecin compound, preparation method therefor, and application thereof |
| US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
| CA3224492A1 (en) | 2021-07-19 | 2023-01-26 | Xiaojun Han | Immunoconjugates and methods |
| JP2024532768A (ja) * | 2021-08-19 | 2024-09-10 | ハイナン シムセレ ザイミン ファーマシューティカル カンパニー リミテッド | カンプトテシン誘導体、その薬物組成物およびその応用 |
| US20250059143A1 (en) * | 2021-10-26 | 2025-02-20 | Shanghai Best-Link Bioscience, Llc | Camptothecin derivative intermediate, and preparation method therefor and use thereof |
| JP7767613B2 (ja) | 2021-11-15 | 2025-11-11 | システィミューン，インコーポレイテッド | 二重特異性抗体－カンプトテシン薬物複合体及びその製薬的使用 |
| US11814394B2 (en) | 2021-11-16 | 2023-11-14 | Genequantum Healthcare (Suzhou) Co., Ltd. | Exatecan derivatives, linker-payloads, and conjugates and thereof |
| TW202344252A (zh) * | 2022-05-09 | 2023-11-16 | 大陸商同宜醫藥（蘇州）有限公司 | 一種喜樹鹼衍生物，基於其的抗體－藥物偶聯物和藥物組成物，及其應用 |
| JP2025515988A (ja) | 2022-05-13 | 2025-05-23 | シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド | カンプトテシン化合物、その調製方法及びその使用 |
| EP4562051A1 (en) * | 2022-07-26 | 2025-06-04 | Immunome, Inc. | Immunoconjugates and methods |
| CN120225528A (zh) * | 2022-09-02 | 2025-06-27 | 默沙东有限责任公司 | 依喜替康衍生的拓扑异构酶-1抑制剂药物组合物及其用途 |
| CN121064211A (zh) * | 2022-09-09 | 2025-12-05 | 杭州爱科瑞思生物医药有限公司 | 喜树碱-7-乙基胺衍生物及其制备方法和应用 |
| AU2023349279A1 (en) * | 2022-09-30 | 2025-05-15 | Beone Medicines I Gmbh | Ligand-drug conjugate of exatecan analogue, and medical use thereof |
| KR20250079213A (ko) | 2022-10-09 | 2025-06-04 | 라노바 메디신즈 리미티드 | 화합물, 조성물 및 방법 |
| KR20250079227A (ko) * | 2022-10-25 | 2025-06-04 | 머크 샤프 앤드 돔 엘엘씨 | 엑사테칸-유래 adc 링커-페이로드, 제약 조성물, 및 그의 용도 |
| EP4623936A1 (en) * | 2022-11-22 | 2025-10-01 | Keymed Biosciences (Chengdu) Co., Ltd. | Fused ring compound, conjugate thereof and use thereof |
| WO2024114318A1 (zh) * | 2022-11-29 | 2024-06-06 | 四川科伦博泰生物医药股份有限公司 | 药物连接子化合物及其制备方法和用途 |
| CN116870187A (zh) * | 2022-12-29 | 2023-10-13 | 杭州爱科瑞思生物医药有限公司 | N-氧杂环烷基取代的喜树碱衍生物的抗体偶联药物 |
| CN116712563A (zh) * | 2022-12-29 | 2023-09-08 | 杭州爱科瑞思生物医药有限公司 | N-卤代烷基取代的喜树碱衍生物的抗体偶联药物 |
| CN116712562A (zh) * | 2022-12-29 | 2023-09-08 | 杭州爱科瑞思生物医药有限公司 | N-叠氮烷基取代的喜树碱衍生物的抗体偶联药物 |
| WO2024158996A2 (en) * | 2023-01-25 | 2024-08-02 | Zeno Management, Inc. | Immunoconjugates and methods |
| IL322897A (en) * | 2023-02-23 | 2025-10-01 | Phrontline Biopharma Hangzhou Co Ltd | Camptothecin derivatives and conjugates, methods for their preparation and medical uses |
| KR20250152646A (ko) * | 2023-03-01 | 2025-10-23 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 인데노[1,2-b]퀴놀린-10,13-디온 유도체의 제조 방법 |
| EP4692091A1 (en) * | 2023-04-07 | 2026-02-11 | Changchun Genescience Pharmaceutical Co., Ltd. | Camptothecin derivative, and pharmaceutical composition, preparation method therefor and use thereof |
| CN116478051B (zh) * | 2023-04-13 | 2024-06-21 | 戊言医药科技（上海）有限公司 | 一种贝洛替康盐酸盐及其关键中间体的制备方法 |
| WO2024227432A1 (zh) * | 2023-04-30 | 2024-11-07 | 泰诚思(上海)生物医药有限公司 | 喜树碱衍生物、其制备方法及用途、抗体药物偶联物及其应用 |
| CN120826405A (zh) * | 2023-05-04 | 2025-10-21 | 四川科伦博泰生物医药股份有限公司 | 具有靶向作用的偶联物及其制备方法和用途 |
| CN117417346B (zh) * | 2023-09-11 | 2025-07-25 | 常州合全药业有限公司 | 喜树碱类衍生物的制备方法 |
| KR20250059577A (ko) | 2023-10-24 | 2025-05-07 | 삼성디스플레이 주식회사 | 표시 장치 |
| CN122161833A (zh) * | 2023-11-15 | 2026-06-05 | 四川科伦博泰生物医药股份有限公司 | 靶向EGFR/c-MET的抗体-药物缀合物及其制备方法和用途 |
| CN120058720A (zh) * | 2024-01-08 | 2025-05-30 | 杭州爱科瑞思生物医药有限公司 | 7-含羟胺结构取代的烷基喜树碱衍生物的制备及其应用 |
| CN120058721A (zh) * | 2024-01-08 | 2025-05-30 | 杭州爱科瑞思生物医药有限公司 | 7-氟烷基取代的喜树碱衍生物的制备及其应用 |
| WO2025162049A1 (zh) * | 2024-02-02 | 2025-08-07 | 长春金赛药业有限责任公司 | 卤代烯烃类喜树碱衍生物、药物组合物及其制备方法和应用 |
| WO2025242090A1 (zh) * | 2024-05-21 | 2025-11-27 | 康诺亚生物医药科技（成都）有限公司 | 喜树碱衍生物及其中间体的制备方法 |
| WO2026046398A1 (en) * | 2024-08-30 | 2026-03-05 | Hansoh Bio Llc | Novel camptothecin derivative and conjugate thereof, preparation method therefor and application thereof |
| WO2026158370A1 (zh) * | 2025-01-24 | 2026-07-30 | 四川科伦博泰生物医药股份有限公司 | 具有生物活性的化合物的制备方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3008226B2 (ja) * | 1991-01-16 | 2000-02-14 | 第一製薬株式会社 | 六環性化合物 |
| JP3359955B2 (ja) * | 1992-07-16 | 2002-12-24 | 第一製薬株式会社 | 抗腫瘍剤 |
| DE69635560T2 (de) * | 1995-06-21 | 2006-08-17 | Société de Conseils de Recherches et D'Applications Scientifiques (S.C.R.A.S.) | Camptothecinanaloge, Verfahren zur ihrer Herstellung, ihre Verwendung als Arzneimittel und diese enthaltende pharmazeutische Zusammensetzungen |
| CA2192725C (en) * | 1995-12-28 | 2004-04-20 | Kenji Tsujihara | Camptothecin derivatives |
| CN100408582C (zh) * | 2004-02-12 | 2008-08-06 | 中国人民解放军第二军医大学 | 高喜树碱类化合物及其制备方法和用途 |
| EP3442979A4 (en) * | 2016-04-04 | 2019-12-18 | Rutgers, the State University of New Jersey | topoisomerase poisons |
| CN110891942B (zh) * | 2017-07-14 | 2022-06-07 | 四川科伦博泰生物医药股份有限公司 | 噁二唑类衍生物、其制备方法及其在医药上的应用 |
| CN119219654A (zh) * | 2017-12-15 | 2024-12-31 | 四川科伦博泰生物医药股份有限公司 | 生物活性物偶联物及其制备方法和用途 |
| CN111936169A (zh) * | 2018-04-06 | 2020-11-13 | 西雅图遗传学公司 | 喜树碱肽缀合物 |
| TWI920652B (zh) * | 2018-06-07 | 2026-04-01 | 美商思進公司 | 喜樹鹼結合物 |
| UA130338C2 (uk) * | 2018-09-26 | 2026-01-28 | Джянгсу Хенгруй Медісін Ко., Лтд. | Кон'югат ліганд-лікарський засіб аналога ексатекану, спосіб його отримання та його застосування |
| JP7408646B2 (ja) * | 2018-09-30 | 2024-01-05 | ジエンス ハンソー ファーマスーティカル グループ カンパニー リミテッド | 抗－ｂ７ｈ３抗体－エキサテカンアナログコンジュゲート及びその医薬用途 |
| KR20240104214A (ko) * | 2019-03-29 | 2024-07-04 | 메디뮨 리미티드 | 화합물 및 이의 접합체 |
| RS64961B1 (sr) * | 2019-04-26 | 2024-01-31 | Immunogen Inc | Derivati kamptotecina |
| CN111689980A (zh) * | 2019-05-26 | 2020-09-22 | 四川百利药业有限责任公司 | 一种喜树碱药物及其抗体偶联物 |
| CN110357897A (zh) * | 2019-07-26 | 2019-10-22 | 上海健康医学院 | 一种具有抗肿瘤活性的喜树碱衍生物及其制备方法和应用 |
| CN112125915A (zh) * | 2019-09-18 | 2020-12-25 | 四川百利药业有限责任公司 | 一种喜树碱衍生物及其偶联物 |
| US20230101735A1 (en) * | 2020-01-22 | 2023-03-30 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-trop-2 antidody-exatecan analog conjugate and medical use thereof |
| BR112022024930A2 (pt) * | 2020-06-08 | 2022-12-27 | Baili Bio Chengdu Pharmaceutical Co Ltd | Fármaco de camptotecina possuindo unidade de conexão hidrofílica de alta estabilidade e conjugado do mesmo |
| WO2022078259A1 (zh) * | 2020-10-12 | 2022-04-21 | 四川百利药业有限责任公司 | 一种氘代的喜树碱衍生物及其抗体药物偶联物 |
| AU2022216696A1 (en) * | 2021-02-05 | 2023-08-17 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Camptothecin compound, preparation method therefor, and application thereof |
| US20240252665A1 (en) * | 2021-06-02 | 2024-08-01 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Chemical coupling linker and use thereof |
| MX2023012920A (es) * | 2021-06-02 | 2023-11-13 | Sichuan Kelun Biotech Biopharmaceutical Co Ltd | Conjugado anticuerpo-farmaco y metodo de preparacion y uso del mismo. |
| US11814394B2 (en) * | 2021-11-16 | 2023-11-14 | Genequantum Healthcare (Suzhou) Co., Ltd. | Exatecan derivatives, linker-payloads, and conjugates and thereof |
| CN117567487A (zh) * | 2023-11-27 | 2024-02-20 | 金宏气体股份有限公司 | 双核Ag(I)配合物晶体、制备方法、负载物、装置及应用 |
-
2022
- 2022-01-27 AU AU2022216696A patent/AU2022216696A1/en active Pending
- 2022-01-27 KR KR1020257024904A patent/KR20250119655A/ko active Pending
- 2022-01-27 CN CN202311518671.2A patent/CN117567478B/zh active Active
- 2022-01-27 KR KR1020257024905A patent/KR20250120438A/ko active Pending
- 2022-01-27 US US18/262,821 patent/US20240158410A1/en active Pending
- 2022-01-27 EP EP25191605.2A patent/EP4613335A3/en active Pending
- 2022-01-27 EP EP25191607.8A patent/EP4628165A3/en active Pending
- 2022-01-27 EP EP22749041.4A patent/EP4289851A4/en active Pending
- 2022-01-27 KR KR1020237025527A patent/KR20230142710A/ko active Pending
- 2022-01-27 CN CN202280008418.XA patent/CN116829561B/zh active Active
- 2022-01-27 CN CN202510232225.8A patent/CN120058723A/zh active Pending
- 2022-01-27 MX MX2023008716A patent/MX2023008716A/es unknown
- 2022-01-27 CA CA3209426A patent/CA3209426A1/en active Pending
- 2022-01-27 JP JP2023544762A patent/JP7821188B2/ja active Active
- 2022-01-27 WO PCT/CN2022/074328 patent/WO2022166762A1/zh not_active Ceased
-
2025
- 2025-07-24 JP JP2025123921A patent/JP2025160317A/ja active Pending
- 2025-07-24 US US19/279,242 patent/US20250346606A1/en active Pending
- 2025-07-24 JP JP2025123923A patent/JP2025160318A/ja active Pending
- 2025-07-24 US US19/279,201 patent/US20260152510A1/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12539336B2 (en) | 2022-07-15 | 2026-02-03 | Genequantum Healthcare (Suzhou) Co., Ltd. | Antibody, linkers, payload, conjugates and applications thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4628165A2 (en) | 2025-10-08 |
| US20260152510A1 (en) | 2026-06-04 |
| JP2025160318A (ja) | 2025-10-22 |
| CN120058723A (zh) | 2025-05-30 |
| CN117567478B (zh) | 2025-03-21 |
| US20240158410A1 (en) | 2024-05-16 |
| CN116829561B (zh) | 2026-07-31 |
| US20250346606A1 (en) | 2025-11-13 |
| MX2023008716A (es) | 2023-08-02 |
| EP4613335A2 (en) | 2025-09-10 |
| KR20250120438A (ko) | 2025-08-08 |
| CN116829561A (zh) | 2023-09-29 |
| EP4613335A3 (en) | 2025-12-10 |
| CN117567478A (zh) | 2024-02-20 |
| EP4289851A4 (en) | 2025-10-15 |
| JP7821188B2 (ja) | 2026-02-26 |
| KR20230142710A (ko) | 2023-10-11 |
| EP4289851A1 (en) | 2023-12-13 |
| KR20250119655A (ko) | 2025-08-07 |
| EP4628165A3 (en) | 2026-03-11 |
| JP2025160317A (ja) | 2025-10-22 |
| JP2024506819A (ja) | 2024-02-15 |
| AU2022216696A1 (en) | 2023-08-17 |
| WO2022166762A1 (zh) | 2022-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7821188B2 (ja) | カンプトテシン化合物、その調製方法、及びその適用 | |
| EP4524140A1 (en) | Camptothecin compound, preparation method therefor and use thereof | |
| EP4373827A1 (en) | Kras g12d inhibitors and uses thereof | |
| ES2262996T3 (es) | Deazapurinas y sus usos. | |
| CN112341450A (zh) | 一种免疫调节剂 | |
| CN107074833B (zh) | 具有β2受体激动及M3受体拮抗活性的苯并环衍生物及其在医药上的用途 | |
| WO2024078581A1 (en) | Selective bcl-xl protac compounds and uses thereof | |
| JP2025526425A (ja) | 抗体薬物複合体に適した毒素分子 | |
| TW202506671A (zh) | 醯胺類化合物、包含其的藥物組合物及其用途 | |
| EP1638978A4 (en) | 7-substituted camptothecin and camptothecin analogs and methods for preparing same | |
| CN117658983A (zh) | 选择性parp1抑制剂 | |
| RU2753036C9 (ru) | Производное триптолида, способ его получения и применение | |
| JP2026504901A (ja) | アザシクロアルカン化合物、医薬組成物及びその使用 | |
| CN115772170A (zh) | 一种吡唑并[1,5-a]吡啶衍生物及其制备方法和应用 | |
| HK40101679B (en) | Camptothecin compound, preparation method therefor, and application thereof | |
| HK40101679A (en) | Camptothecin compound, preparation method therefor, and application thereof | |
| WO2013064029A1 (zh) | 具有抗癌活性的苯甲酰脲衍生物及其制备方法和用途 | |
| CN120858098A (zh) | 稠环化合物及其制备方法和应用 | |
| WO2026098309A1 (zh) | 多并环类化合物及其制备方法和用途 | |
| CN116283764A (zh) | 硝羟喹啉前药及其制备方法和用途 | |
| HK40066300A (en) | Compound as porcupine inhibitor and use thereof | |
| WO2022010882A1 (en) | Dihydroquinoxaline and dihydropyridopyrazine derivatives as rsv inhibitors | |
| JPH09227559A (ja) | スピロ置換三環性複素環式化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241213 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241213 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20251216 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251216 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251218 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251218 |